We are seeking people to take part in a research study into whether vitamin B3 tablets reduce the number of new non-melanoma skin cancers and actinic (sun-induced) keratoses (sun spots) in people who have had an organ transplant, and who have also had previous skin cancers.
This study aims to see how effective a new blood test (using a diagnostic test called EUROIMMUN biochip) is in diagnosing and monitoring autoimmune blistering skin diseases, in comparison to the standard blood test.
Participants will be asked to donate an additional sample of blood which will be used for research into genetic susceptibility to autoimmune blistering skin disease. Only one visit is required and this usually will occur at the time of your visit at The Royal Melbourne Hospital.
This study has been designed to understand more about the day to day impact psoriasis has on the life of patients being treated with secukinumab. Participation includes completing quality of life surveys are your normal visits to see the effect of treatment.
We, here at the Royal Melbourne Hospital, are currently running a non-interventional research study for people who suffer with Hidradenitis Suppurativa, Pyoderma Gangrenosum or Palmoplantar Pustulosis. All of these conditions fall under the umbrella of neutrophilic skin conditions or diseases.
This research project aims to develop test methods to use in a future clinical trial for testing possible new treatments for patients with neutrophilic skin conditions or diseases, and to find out more about the causes of these conditions.
This post-market study involves collecting information for an already approved VNS device. This type of study is conducted for many medications or medical devices to get detailed information about the outcomes of people receiving an approved treatment.
People participating in this study must be deemed appropriate for VNS treatment by their treating doctors and be planned for surgery at The Royal Melbourne Hospital.
The purpose of this study is to better understand the following areas of health for people who receive VNS treatment:
- Anti-epileptic treatment and medication taken by people who have had a VNS device implanted
- Frequency and severity of seizures
- Quality of life and quality of sleep (reported through questionnaires)
- What types of healthcare services are being used
- Details of the settings used on the VNS device
The research study is testing a new treatment for vascular dementia (VaD) and Alzheimer’s disease with cerebrovascular disease. The new treatment is called Sailuotong (SLT). SLT is an extract of three standardised Chinese herbs, Ginseng, Ginkgo and Saffron, all of which are individually permitted for over-the-counter sale in Australia.
The primary objective is to determine the effectiveness of the herbal intervention on cognitive function (the brain functions relating to attention, memory, judgement, reasoning, problem solving etc.), activities of daily living and quality of life, and monitor the safety and effectiveness of SLT.
A gluten-free diet is the only current treatment for coeliac disease but it is complex and not always effective. Even patients who strictly adhere to it can suffer short and long-term adverse effects from gluten exposure.
We are seeking participants for a study testing a new experimental treatment for coeliac disease called Nexvax2. It is a Phase 2 double-blind, randomized, placebo-controlled, multicentre study. The study consists of 3 periods: a screening period of 6 weeks, an approximately 16 week treatment period, and a 4 week observational follow-up period.
This research project is testing a new treatment for locally advanced or metastatic ER-positive breast cancer. The new treatment is called venetoclax given in combination with fulvestrant and we we want to know whether adding venetoclax will add to the effectiveness of the fulvestrant.
Fulvestrant is a drug that is designed to bind to the oestrogen receptors, completely blocking the ability of oestrogen to attach to these receptors. This can help to slow down the growth of ER-positive breast cancer.
Venetoclax has been approved for treatment of a type of leukaemia. In this study, venetoclax is an experimental drug, which means health authorties have not approved it in combination with fulvestrant for the treatment of ER-positive breast cancer.